PODD vs DXCM vs TNDM vs NVCR vs ITGR

For growth investors, Insulet Corporation (PODD) is the stronger pick with 30.

7% revenue growth year-over-year, versus 7. 6% for Integer Holdings Corporation (ITGR). DexCom, Inc. (DXCM) offers the better valuation at 29. 1x trailing P/E (24. 5x forward), making it the more compelling value choice. Analysts rate Insulet Corporation (PODD) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, DexCom, Inc.

(DXCM) is the cheapest at 29. 1x versus Insulet Corporation at 46. 1x. On forward P/E, Integer Holdings Corporation is actually cheaper at 13. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Insulet Corporation wins at 0. 24x versus Integer Holdings Corporation's 3. 08x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Integer Holdings Corporation (ITGR) delivered a total return of -7.

5%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: PODD returned +439. 0% versus TNDM's -75. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Insulet Corporation (PODD) is the lower-risk stock at 0.

68β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 222% more volatile than PODD relative to the S&P 500. On balance sheet safety, DexCom, Inc. (DXCM) carries a lower debt/equity ratio of 51% versus 3% for Tandem Diabetes Care, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Insulet Corporation (PODD) is pulling ahead at 30.

7% versus 7. 6% for Integer Holdings Corporation (ITGR). On earnings-per-share growth, the picture is similar: DexCom, Inc. grew EPS 47. 2% year-over-year, compared to -106. 8% for Tandem Diabetes Care, Inc.. Over a 3-year CAGR, PODD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DexCom, Inc.

(DXCM) is the more profitable company, earning 17. 9% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 17. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DXCM leads at 19. 6% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Insulet Corporation (PODD) is the more undervalued stock at a PEG of 0. 24x versus Integer Holdings Corporation's 3. 08x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Integer Holdings Corporation (ITGR) trades at 13. 5x forward P/E versus 25. 2x for Insulet Corporation — 11. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PODD: 111. 3% to $339. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Insulet Corporation (PODD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

68), +439. 0% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PODD: +439. 0%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PODD is a mid-cap high-growth stock; DXCM is a mid-cap high-growth stock; TNDM is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ITGR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.